Bifascicular nature of the flexor digitorum profundus and flexor pollicis longus tendons: forgotten anatomical characteristics rediscovered with US imaging.

OBJECTIVES: To demonstrate the bifid configuration of the flexor digitorum profundus (FDP) and flexor pollicis longus (FPL). METHODS: In the first part of this study, 20 digits from 4 cadaver hands were dissected and analyzed using anatomical and histological slices. The second part of the study was carried out over a 12-month period starting in August 2018. It was a prospective US imaging study of 300 digits from 30 healthy participants performed by two radiologists in a double-blinded manner. This study focused on two items: tendon shape and whether a central septum separated the two hemitendons. Descriptive statistics were calculated along with the inter-rater reliability. RESULTS: In 100% (300/300) of fingers and thumbs, the FDP and FPL tendons were made up of two parallel bundles arranged side by side, with a central vertical septum between these two hemitendons, starting at the head of the proximal phalanx (PP) and continuing distally. This central septum was always present starting at the proximal third of PP for the FDP of the index, middle, and ring fingers. The septum was more difficult to identify in the thumb and little finger. Cohen's kappa indicated near perfect agreement when all digits were considered together (≥ 0.9), and substantial agreement for the thumb (0.71) and for the little finger (0.82). CONCLUSIONS: With US imaging, the bifascicular nature of the FDP and FPL tendons is easy to see, as these tendons have a double-barreled configuration starting at the head of the proximal phalanx. KEY POINTS: •Analysis of anatomical slices of the hand tendons found a bifascicular appearance of the flexor digitorum profundus and flexor pollicis longus tendons starting at the head of the proximal phalanx. •This distinct feature of two hemitendons arranged side by side was seen in 100% of tendons we examined with US. It is associated with a vertical central septum that causes anisotropy. •Awareness of this "forgotten" anatomical detail has practical implications when interpreting images generated by latest-generation US systems and during surgery on hand flexor tendons.

Percutaneous cryoablation of abdominal wall endometriosis: An analysis of 38 patients.

PURPOSE: The purpose of this study was to evaluate the efficacy of percutaneous cryoablation in the treatment of abdominal wall endometriosis (AWE) nodules. MATERIALS AND METHODS: Thirty-eight women treated for symptomatic AWE nodules with percutaneous cryoablation under ultrasound and computed tomography (CT) guidance between May 2020 and July 2023 were retrospectively included. Pain was estimated using visual analog scale (VAS) and assessed at baseline, three months, six months, and 12 months after percutaneous cryoablation. Baseline VAS score, volume of AWE nodule and magnetic resonance imaging (MRI) features of AWE nodules were compared to those obtained after percutaneous cryoablation. Major complications, if any, were noted. RESULTS: Thirty-eight women with a median age of 35.5 years (interquartile range [IQR]: 32, 39; range: 24-48 years) and a total of 60 AWE nodules were treated. Percutaneous cryoablation was performed under local or regional anesthesia in 30 women (30/38; 79%). Significant decreases between initial median VAS score (7; IQR: 6, 8; range: 3-10) and median VAS score after treatment at three months (0; IQR: 0, 5; range; 0-8) (P < 0.001), six months (0; IQR: 0, 1; range; 0-10) (P < 0.001) and 12 months (0; IQR: 0, 2; range: 0-7) (P < 0.001) were observed. Percutaneous cryoablation resulted in effective pain relief in 31 out of 38 women (82%) at six months and 15 out of 18 women (83%) at 12 months. Contrast-enhanced MRI at six-month follow-up showed a significant decrease in the volume of AWE nodules and the absence of AWE nodule enhancement after treatment by comparison with baseline MRI (P < 0.001). No major complications were reported. CONCLUSION: Percutaneous cryoablation is an effective, minimally invasive intervention for the treatment of AWE nodules that conveys minimal or no morbidity.